Avaxia Biologics Receives $6,400,000 Series B Funding

  • Feed Type
  • Date
    12/18/2012
  • Company Name
    Avaxia Biologics
  • Mailing Address
    128 Spring Street Lexington, MA 02421
  • Company Description
    Avaxia is developing oral antibody products for diseases and disease targets that can be reached through the mouth and the gastrointestinal tract.
  • Website
    http://www.avaxiabiologics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $6,400,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Avaxia plans to use the proceeds to fund a first-in-human Phase 1b clinical trial of its oral anti-TNF antibody, AVX-470, for the treatment of ulcerative colitis.
  • M&A Terms
  • Venture Investor
    Cherrystone Angel Group
  • Venture Investor
    Golden Seeds
  • Venture Investor
    Beacon Angels
  • Venture Investor
    Boston Harbor Angels
  • Venture Investor
    Launchpad Venture Group
  • Venture Investor
    Beta Fund
  • Venture Investor
    Granite State Angels
  • Venture Investor
    Maine Angels
  • Venture Investor
    Keiretsu Forum – Boston/New England

By posting a comment, you agree to our terms and conditions.